Update on hydroxychloroquine use in pregnancy

查看全文 作　　者：Wassan [1]Nori;Nabeeha Najatee [2]Akram;Raid M Al-[3]Ani 机构地区：[1]Department of Obstetrics and Gynecology,Mustansiriyah University,Baghdad 10052,Iraq;[2]Department of Pediatrics,Mustansiriyah University,Baghdad 10052,Iraq;[3]Department of Surgery/Otolaryngology,University of Anbar,Anbar 31001,Iraq 出　　处：《World Journal of Experimental Medicine》索引2023年第13卷第4期,共3页 摘　　要：It is well-known that hydroxychloroquine(HCQ)treats malaria,systemic lupus erythematosus,and rheumatoid arthritis in women for its immunomodulatory and anti-inflammatory action.Additionally,HCQ was used in cases with refractory antiphospholipid syndrome.HCQ safety was reinforced in pregnant women owing to insignificant reports of adverse pregnancy outcomes and major congenital malformation.Recently,HCQ was tested in cases with chronic placental inflammation with a promising result of increased life birth;however,its benefit needs further validation.We aimed to highlight the recent updates for HCQ use in various conditions in pregnancy. 关 键 词：PREGNANCY HYDROXYCHLOROQUINE PREECLAMPSIA Antiphospholipid syndrome Chronic placental inflammation COVID-19